ImmunoCellular Therapeutics Ltd(NYSEMKT:IMUC) shares added 2.12% to $1.01. ImmunoCellular Therapeutics, Ltd. is a clinical-stage biotechnology company. The Company is engaged in developing immune-based therapies for the treatment of cancers, such as brain, ovarian and other solid tumors. Immunotherapy is an approach to treat cancer in which a patient’s own immune system is stimulated to target tumor antigens, which are molecular signals that the immune system uses to identify foreign bodies.
Free Urgent Insider Catalyst Report For IMUC Available Here
Celgene Corporation(NASDAQ:CELG) shares increased 0.91% to $171.35. Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases. It is engaged in the research and development, which is designed to bring new therapies to market, and is engaged in research in several scientific areas that may deliver therapies, focusing areas, such as intracellular signaling pathways in cancer and immune cells, immunomodulation in cancer and autoimmune diseases, and therapeutic application of cell therapies.
Free Urgent Insider Catalyst Report For CELG Available Here
Zalicus Inc(NASDAQ:ZLCS) shares added 2.45% to $1.68. Zalicus Inc. (Zalicus) is a biopharmaceutical company that discovers and developsl treatments for patients suffering from pain and immuno-inflammatory diseases. The Company has a portfolio of clinical-stage product candidates targeting pain and immuno-inflammatory diseases and have entered into multiple revenue-generating collaborations with large pharmaceutical companies relating to other products, product candidates and drug discovery technologies.
Free Urgent Insider Catalyst Report For ZLCS Available Here
Exelixis, Inc.(NASDAQ:EXEL) shares gained 5.91% to $7.88. Exelixis, Inc. (Exelixis) is a biotechnology company engaged in developing small molecule therapies for the treatment of cancer. The Company is focusing its resources and development efforts on cabozantinib (XL184). It also has a portfolio of other compounds. Cabozantinib is the inhibitor of MET in clinical development and is being evaluated in a development program encompassing multiple cancer indications.
Free Urgent Insider Catalyst Report For EXEL Available Here